atenolol has been researched along with losartan in 281 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (4.27) | 18.2507 |
| 2000's | 192 (68.33) | 29.6817 |
| 2010's | 68 (24.20) | 24.3611 |
| 2020's | 9 (3.20) | 2.80 |
| Authors | Studies |
|---|---|
| Funakoshi, J; Kakumoto, M; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dahlöf, B; Goldberg, AI; Keller, SE; Lim, NY; Makris, L; Sweet, CS | 1 |
| Goldberg, A; Sweet, C | 1 |
| Dunlay, MC; Goldberg, AI; Sweet, CS | 2 |
| Hajj-Ali, AF; Wong, PC | 1 |
| Hilgenfeldt, U; Schwind, S | 1 |
| Couch, SJ; Pals, DT | 1 |
| Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS | 1 |
| Dahlöf, B; de Faire, U; Devereux, R; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, S; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H | 1 |
| Brown, MJ | 1 |
| Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H | 1 |
| Alesse, E; Bravi, MC; Desideri, G; Ferri, C; Gulino, A; Martinotti, S; Pastore, L; Santucci, A; Tessitore, A; Toniato, E | 1 |
| Intengan, HD; Park, JB; Schiffrin, EL; Touyz, RM | 1 |
| Grote, L; Hedner, J; Kraiczi, H; Peker, Y | 1 |
| Baiz, AQ; Bortman, G; Farsang, C; Garcia-Puig, J; Niegowska, J; Vrijens, F | 1 |
| Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H | 1 |
| Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM | 1 |
| Elghozi, JL; Girard, A; Holand, S; Laude, D | 1 |
| Khazine, F; Simons, O | 1 |
| Ball, KJ; Stumpe, KO; Williams, PA | 1 |
| Björnstad, H; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Giles, TD; Palmieri, V; Papademetriou, V; Wachtell, K | 1 |
| Aalto, T; Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Palmieri, V; Papademetriou, V; Rokkedal, J; Wachtell, K | 1 |
| Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H | 1 |
| Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H | 1 |
| Oparil, S | 1 |
| Einecke, D | 1 |
| Hernborg, A; Liedholm, H; Melander, A; Werkö, L | 1 |
| Järhult, B | 1 |
| Kahan, T; Nilsson, P | 1 |
| Schiffrin, EL | 1 |
| Heinzl, S | 1 |
| Rapi, J | 1 |
| Scheen, AJ | 1 |
| Wiedermann, CJ | 1 |
| Hamon, M | 1 |
| Cruickshank, JM | 1 |
| Bloom, JM | 1 |
| Brown, MJ; Cockcroft, JR | 1 |
| Lapeyre-Mestre, M; Montastruc, JL; Pathak, A | 1 |
| Fuchs, FD | 1 |
| Fritschka, E; Ludwig, M; Ribeiro, A; Smith, RD; Stapff, M; Stumpe, KO; Tholl, U | 1 |
| Aurup, P; Barrios, V; Dahlof, B; Diez, J; Johansson, M; Nicholls, MG; Smith, RD; Yu, CM; Zanchetti, A | 1 |
| Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H | 1 |
| Malik, RA | 1 |
| Böhm, S | 1 |
| González-Juanatey, JR | 1 |
| Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H | 1 |
| Van Brabandt, H | 1 |
| Vandenbroucke, JP | 2 |
| Dominiak, P; Zidek, W | 1 |
| Zidek, W | 1 |
| Lester, MH; Resnick, LM | 1 |
| Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Papademetriou, V; Rokkedal, J; Smith, G; Wachtell, K | 1 |
| Karpov, IuA | 1 |
| Adams, HP | 1 |
| Schmieder, RE; Schneider, MP | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Pfeffer, M | 1 |
| de Boer, RA; Gans, RO; Gansevoort, RT; van Veldhuisen, DJ | 1 |
| Werkö, L | 1 |
| Fournier, A; Grossman, E; Messerli, FH | 1 |
| Achard, JM; Andrejak, M; Fernandez, L; Fournier, A; Oprisiu, R | 1 |
| Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL | 1 |
| Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL | 1 |
| Messerli, FH | 2 |
| Böhm, M; Fries, R | 1 |
| Lim, HS; Lip, GY; Nadar, S | 1 |
| Schunkert, H | 1 |
| Liebson, PR | 1 |
| Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Papademetriou, V; Toivonen, L; Viitasalo, M; Wachtell, K | 1 |
| Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM | 1 |
| Aurup, P; Dahlof, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Okin, PM; Snapinn, S | 1 |
| Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Helle Berg, S; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H | 1 |
| Aronow, WS | 1 |
| Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K | 1 |
| Baumgart, P | 3 |
| Diener, HC | 1 |
| Sidorenko, BA; Ugriumova, MO | 1 |
| Albino-Teixeira, A; Guimarães, S; Morato, M; Moura, D; Sousa, T | 1 |
| Brainin, M; Finsterer, J; Slany, J; Stöllberger, C | 1 |
| Arend, A; Aunapuu, M; Ots, M; Pechter, U; Suuroja, T | 1 |
| Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Pasotti, C; Preti, P; Zoppi, A | 1 |
| Ong, HT | 1 |
| Chong, AY; Lip, GY | 1 |
| Beloqui, O; Díez, J; González, A; Laviades, C; López, B; Mayor, G; Orbe, J; Páramo, JA; Zalba, G | 1 |
| Chen, C; Snapinn, SM; Wang, H | 1 |
| Alderman, MH; Chen, C; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H | 1 |
| Alderman, MH; Beevers, G; Dahlöf, B; Devereux, RB; Douglas, JG; Edelman, JM; Harris, KE; Julius, S; Kjeldsen, SE; Nesbitt, S; Randall, OS; Wright, JT | 1 |
| Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K | 1 |
| Liakishev, AA | 1 |
| Bratland, B; Gerhardsen, G; Gisholt, K; Kjeldsen, SE; Omvik, P; Risanger, T; Smedsrud, T | 1 |
| Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Koren, MJ; Liu, JE; Nieminen, MS; Palmieri, V; Wachtell, K; Wright, JT; Zabalgoitia, M | 1 |
| Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Liu, JE; Nieminen, MS; Oikarinen, L; Okin, PM; Wachtell, K | 1 |
| Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Roman, MJ; Smith, G; Wachtell, K | 1 |
| Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H | 2 |
| Beevers, DG | 1 |
| Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Snapinn, S; Toivonen, L; Viitasalo, M | 1 |
| Aunapuu, M; Kullissaar, T; Ots, M; Pechter, U; Riispere, Z; Vihalemm, T; Zilmer, K; Zilmer, M | 1 |
| Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, P; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K | 1 |
| Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A | 1 |
| Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y | 2 |
| Boman, K; Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K | 1 |
| Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Liu, JE; Nieminen, MS; Olsen, MH; Papademetriou, V; Rokkedal, J; Wachtell, K | 1 |
| Devereux, RB; Lyle, PA | 1 |
| Aurup, P; Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Snapinn, S; Wedel, H | 1 |
| Aurup, P; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Harris, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K | 1 |
| Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H | 1 |
| Burnier, M; Erne, P; Szucs, TD | 1 |
| Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K | 1 |
| Bourassa, MG | 1 |
| Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K | 1 |
| Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H | 1 |
| Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H | 1 |
| Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K | 1 |
| Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K | 1 |
| O'Rourke, MF; Safar, ME | 2 |
| Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH | 1 |
| Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T | 1 |
| Bella, JN; Dige-Petersen, H; Ibsen, H; Neland, K; Olsen, MH; Rokkedal, J; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Franklin, SS; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Olsen, MH; Papademetriou, V; Wachtell, K | 1 |
| Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H | 1 |
| Hara, Y; Higaki, J; Miki, T; Ogimoto, A; Ohtsuka, T; Shigematsu, Y | 1 |
| Nattel, S | 1 |
| Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Ibsen, H; Nieminen, MS; Olsen, MH; Palmieri, V; Smith, G; Wachtell, K | 1 |
| Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z | 1 |
| Weber, MA | 1 |
| Chao, AC; Chen, YY; Chern, CM; Hsu, HY; Hsu, LC; Hu, HH | 1 |
| Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y | 1 |
| Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y | 1 |
| Band, M; Carr, E; Davies, J; Morris, A; Struthers, A | 1 |
| Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Oikarinen, L; Okin, PM; Olsen, MH; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM | 1 |
| Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Lyle, PA; Nieminen, MS; Olsen, MH; Wachtell, K | 1 |
| Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J | 1 |
| Dahlöf, B; Devereux, RB; Hall, C; Hildebrandt, PR; Ibsen, H; Kjeldsen, SE; Nielsen, OW; Olsen, MH; Wachtell, K; Wergeland, R | 1 |
| Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Hille, DA; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K | 1 |
| Coelho, EB; da Silva, CA; Fazan, R; Nobre, F; Salgado, HC | 1 |
| Björnstad, H; Davidsen, ES; Devereux, RB; Gerdts, E; Lund-Jhansen, P; Omvik, P | 1 |
| Burke, T; Carides, GW; Hildebrandt, P; Keiding, H | 1 |
| Bang, LE; Christensen, MK; Devereux, RB; Fossum, E; Hildebrandt, P; Ibsen, H; Kjeldsen, SE; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K; Wiinberg, N | 1 |
| Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Oikarinen, L; Omvik, P; Otterstad, JE; Wachtell, K | 1 |
| Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H | 1 |
| Dahlöf, B; Devereux, RB | 1 |
| Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P | 1 |
| Chiara Cavallini, M; Palmieri, V; Pini, R | 1 |
| Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K | 1 |
| Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA | 1 |
| Chattopadhyay, A; Dahlöf, B; Devereux, RB; Flaa, A; Hille, DA; Høieggen, A; Iversen, EK; Kjeldsen, SE; Lyle, PA; Olsen, MH; Os, I; Smebye, ML | 1 |
| Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM | 1 |
| Barba, J; Castellano, JM; Díez, J; González, A; López, B | 1 |
| Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA | 1 |
| Bradley, TJ; Colan, SD; Devereux, RB; Dietz, HC; Klein, GL; Lacro, RV; Li, JS; Mahony, L; Minich, LL; Paridon, SM; Pearson, GD; Printz, BF; Pyeritz, RE; Radojewski, E; Roman, MJ; Saul, JP; Stylianou, MP; Wruck, LM | 1 |
| Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM | 1 |
| Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S | 1 |
| Bang, LE; Hildebrandt, PR; Ibsen, H; Larsen, J; Olsen, MH; Tuxen, C; Wachtell, K; Wiinberg, N | 1 |
| Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K | 1 |
| Boman, K; Cramariuc, D; de Simone, G; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I | 1 |
| Garzoni, LR; Henriques, Md; Lessa, MA; Levy, BI; Nascimento, AR; Rodrigues, CA; Sabino, B; Tibiriçá, E | 1 |
| Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Ibsen, H; Jern, S; Kjeldsen, SE; Li, Z; Nieminen, MS; Okin, PM; Wachtell, K | 1 |
| Cramariuc, D; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Wachtell, K | 1 |
| Mourad, JJ; Waeber, B | 1 |
| Avanza, AC; Mansur, AP; Ramires, JA | 1 |
| Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Narayan, P; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H | 1 |
| Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M | 2 |
| Dahlöf, B; Devereux, RB; Franklin, S; Gerdts, E; Nieminen, M; Papademetriou, V; Rieck, A; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; John, M; Kjeldsen, SE; Morin, DP; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M | 1 |
| Brody, R; Grossman, E; Peleg, E; Sharabi, Y | 1 |
| Gopinathannair, R; Olshansky, B; Sullivan, RM | 1 |
| Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K | 1 |
| Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M | 1 |
| Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Okin, PM | 1 |
| Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H | 1 |
| Adachi, K; Furuta, K; Kinoshita, Y; Koshino, K; Miki, M; Morita, T; Nakata, S; Ohara, S; Tanimura, T; Yoshida, K | 1 |
| Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM | 1 |
| Dahlöf, B; Devereux, RB; Kjeldsen, SE; Okin, PM; Olsen, MH; Søraas, CL; Tønnessen, T; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP | 1 |
| Aurigemma, GP; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Okin, PM; Olsen, MH; Palmieri, V; Rokkedal, JE; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K | 2 |
| Cameron, A; Ewen, M; Laing, RO; van Mourik, MS | 1 |
| Angeli, F; Mazzotta, G; Reboldi, G; Verdecchia, P | 1 |
| Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Okin, PM | 1 |
| de Cavanagh, EM; Ferder, LF; Ferder, MD; Inserra, F; Stella, IY; Toblli, JE | 1 |
| Cunha, FM; Fontes, V; Gusmão, JL; Ignez, EC; Mano, GP; Mion, D; Nishiura, JL; Ortega, KC; Pierin, AM; Segre, CA; Ventura, CG | 1 |
| Chavan, UB; Deshpande, AD; Dighe, SB; Jagdale, SN; Kothapalli, LP; Nanda, RK; Thomas, AB | 1 |
| Hosseini, F; Mahmoudian, M; Nemati, F; Rahbar-Roshandel, N; Shafiei, M | 1 |
| Centeno, J; Cortina, J; Evangelista, A; Forteza, A; García, D; García-Dorado, D; Gutiérrez, L; Rodríguez-Palomares, J; Sánchez, V; Sanz, P; Teixidó, G | 1 |
| Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Kontula, K; Os, I; Saijonmaa, O; Silventoinen, K | 1 |
| Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K | 1 |
| Jan, MY; Wang, SH; Wang, WK; Wang, YY | 1 |
| Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Okin, PM; Olsen, MH; Reims, HM; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Kjeldsen, SE; Lindholm, LH; Okin, PM | 1 |
| Berwanger, O; Mion Júnior, D; Ortega, KC; Silva, GV; Tsuji, RL | 1 |
| Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM | 1 |
| Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Olsen, MH; Ruwald, AC; Sehestedt, T; Wachtell, K; Westergaard, B | 1 |
| Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Greve, AM; Lønnebakken, MT; Nieminen, MS; Okin, PM; Olsen, MH; Omvik, P; Palmieri, V; Wachtell, K | 1 |
| Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K | 1 |
| Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH | 1 |
| Bradley, TJ; Campbell, MJ; Chen, S; Cohen, MS; Colan, SD; De Backer, J; Guey, LT; Heydarian, H; Lacro, RV; Lai, WW; Levine, JC; Lewin, MB; Marcus, E; Mart, CR; Pearson, GD; Pignatelli, RH; Printz, BF; Selamet Tierney, ES; Sharkey, AM; Shirali, GS; Sleeper, LA; Srivastava, S | 1 |
| Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP | 1 |
| Benson, DW; Bradley, TJ; De Backer, J; Dietz, HC; Forbus, GA; Gelb, BD; Guey, LT; Klein, GL; Lacro, RV; Lai, WW; Levine, JC; Lewin, MB; Loeys, BL; Mahony, L; Markham, LW; Paridon, SM; Pearson, GD; Pierpont, ME; Radojewski, E; Selamet Tierney, ES; Sharkey, AM; Wechsler, SB; Yetman, AT | 1 |
| Abdelhai, YM; Boman, K; Dahlöf, B; De Simone, G; Devereux, RB; Gerdts, E; Lønnebakken, MT; Mancusi, C; Wachtell, K | 1 |
| Jeffers, BW; Wang, JG; Yan, P | 1 |
| Aurigemma, GP; Bang, CN; Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Køber, L; Wachtell, K | 1 |
| Anhê, GF; Antunes, E; Calmasini, F; Faria, Jde A; Mónica, FZ; Moscoso, JA; Ramos-Filho, AC | 1 |
| Avasthi, R; Dastidaro, DG; Guha, S; Majumdar, D; Mani, S; Mitra, M; Mondal, MM; Mookerjee, S; Narain, VS; Rajendiran, C; Ray, S; Saha, J | 1 |
| Bowen, JM; Connolly, HM | 1 |
| Atz, AM; Benson, DW; Bradley, TJ; Braverman, AC; Chen, S; Colan, SD; De Backer, J; Dietz, HC; Gelb, BD; Grossfeld, PD; Klein, GL; Lacro, RV; Lai, WW; Levine, JC; Liou, A; Loeys, BL; Mahony, L; Markham, LW; Olson, AK; Paridon, SM; Pearson, GD; Pemberton, VL; Pierpont, ME; Pyeritz, RE; Radojewski, E; Roman, MJ; Selamet Tierney, ES; Sharkey, AM; Sleeper, LA; Stylianou, MP; Wechsler, SB; Yetman, AT; Young, LT | 1 |
| Alghamdi, MH; Kiess, M; Potts, JE; Potts, MT; Raffin, LA; Sandor, GG; van Breemen, C; Williams, LD | 1 |
| Dietz, HC; Lacro, RV; Mahony, L | 1 |
| Elefteriades, JA; Mukherjee, SK; Ziganshin, BA | 1 |
| Mohiaddin, R; Pepper, J; Treasure, T | 1 |
| Mallat, Z; Tedgui, A | 1 |
| Bhatt, AB; Buck, JS; Creager, MA; Gauvreau, K; Kadivar, S; Milian, J; Singh, MN; Zuflacht, JP | 1 |
| Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Larstorp, AC; Okin, PM; Wachtell, K | 1 |
| Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K | 1 |
| Beau-Salinas, F; Bejan-Angoulvant, T; Jonville-Béra, AP; Lengellé, C | 1 |
| Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K | 1 |
| Centeno, J; Cortina, J; Evangelista, A; Ferreira-González, I; Forteza, A; García-Dorado, D; Gracia, T; Gutiérrez, L; Rodríguez-Palomares, J; Rufilanchas, JJ; Sánchez, V; Sanz, P; Teixidó-Turà, G | 1 |
| Adji, A; O'Rourke, MF; Weber, T | 1 |
| Devereux, RB; Kamel, H; Kjeldsen, SE; Okin, PM | 1 |
| Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Lønnebakken, MT; Mancusi, C; Midtbø, H; Wachtell, K | 1 |
| Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM | 1 |
| Devereux, RB; Kjeldsen, SE; Okin, PM | 2 |
| Bradley, TJ; Campbell, MJ; Chen, S; Cohen, MS; Colan, SD; De Backer, J; Heydarian, H; Hoskoppal, A; Lacro, RV; Lai, WW; Levine, JC; Liou, A; Marcus, E; Nutting, A; Olson, AK; Parra, DA; Pearson, GD; Pierpont, ME; Printz, BF; Pyeritz, RE; Ravekes, W; Roman, MJ; Selamet Tierney, ES; Sharkey, AM; Sleeper, LA; Srivastava, S; Young, L | 1 |
| Bonomini, HIM; De Sousa, FB; Lopes, JF; Meira, LHR; Soares, GAB | 1 |
| de Moura Leão, MF; de Oliveira, LFS; Duarte, JA; Machado, MM; Piccoli, JDCE; Sauzen, PD | 1 |
| Crosson, JE; Czosek, RJ; Lacro, RV; Love, BA; Mah, DY; McCrindle, BW; Muiño-Mosquera, L; Olson, AK; Pilcher, TA; Shah, MJ; Sleeper, LA; Tierney, ESS; Wechsler, SB; Young, LT | 1 |
| Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G | 1 |
| Isselbacher, EM | 1 |
| Atz, TW; Bradley, TJ; Cappella, E; De Nobele, S; Groh, GK; Hamstra, MS; Handisides, JC; Hollenbeck-Pringle, D; Korsin, R; Lacro, RV; Levine, JC; Lindauer, B; Liou, A; Markham, LW; Morrison, T; Mussatto, KA; Neal, MKM; Olson, AK; Pemberton, VL; Pierpont, MEM; Pyeritz, RE; Radojewski, EA; Roman, MJ; Trachtenberg, FL; Uzark, K; Xu, M | 1 |
| Dietz, HC; Forbus, GA; Gelb, BD; Goldmuntz, E; Hoskoppal, A; James, J; Lacro, RV; Lee, TM; Levine, JC; Li, JS; Loeys, BL; Markham, LW; Meester, JAN; Mital, S; Morris, SA; Mosley, JD; Olson, AK; Renard, M; Roden, DM; Shaffer, CM; Sharkey, A; Sleeper, LA; Van Driest, SL; Young, L | 1 |
| Atz, AM; Cappella, E; Cnota, JF; Dagincourt, N; De Nobele, S; Grima, J; Hamstra, MS; Hollenbeck-Pringle, D; King, M; Korsin, R; Lacro, RV; Lambert, LM; MacCarrick, G; MacNeal, MK; Markham, LW; Pemberton, VL; Sylvester, DM; Trachtenberg, FL; Walter, P; Xu, M | 1 |
| Colan, SD; Flyer, JN; Lacro, RV; Singh, MN; Sleeper, LA | 1 |
| Ayers, R; Iannucci, G; Kelleman, M; McCracken, C; Oster, ME | 1 |
| Begum, S; Ferdousi, S; Sultana, S | 1 |
| Correia, AT; de Oliveira, TMN; Guimarães, LL; Pisetta, AM; Roveri, V | 1 |
| Correia, AT; Guimarães, LL; Roveri, V; Toma, W | 1 |
| Carmichael, HL; Cox, DA; Minich, LL; Ou, Z; Robertson, DM; Selamet Tierney, ES; Truong, DT; Williams, RV | 1 |
| A Wartolowska, K; André, E; Biessels, GJ; Bousser, MG; Dichgans, M; Duering, M; Kerkhofs, D; Kopczak, A; Mansmann, U; Middeke, M; N Doubal, F; Norrving, B; Onkenhout, L; Rothwell, PM; S Stringer, M; Staals, J; Thrippleton, MJ; van den Brink, H; van Dinther, M; van Oostenbrugge, R; W Blair, G; Wardlaw, JM; Webb, AJ | 1 |
15 review(s) available for atenolol and losartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Irbesartan treatment in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Enalapril; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles | 1998 |
[Results from the LIFE study: promising effects of new hypertensive agents].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Atenolol; Biphenyl Compounds; Cilazapril; Humans; Hypertension; Irbesartan; Losartan; Perindopril; Tetrazoles | 2002 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Controlled Clinical Trials as Topic; Drug Administration Schedule; Enalapril; Half-Life; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2002 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Complications; Diastole; Diuretics; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Losartan; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Risk; Risk Factors; Stroke; Systole; Tetrazoles; Time Factors | 2002 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studies; Heart Failure; Heparin, Low-Molecular-Weight; Humans; Hypertension; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Losartan; Magnetic Resonance Angiography; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Primary Prevention; Risk Factors; Sex Factors; Stents; Thrombolytic Therapy; Time Factors; Vitamins | 2003 |
Implications of the LIFE trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Diabetes Complications; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[New perspectives of the use of angiotensin II receptor blocker].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Losartan; Receptors, Angiotensin | 2003 |
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic | 2004 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Cardiovascular Diseases; Clinical Trials as Topic; Enalapril; Ethanolamines; Female; Heart Failure; Hemodynamics; Humans; Hypertension; Labetalol; Losartan; Male; Metoprolol; Middle Aged; Nebivolol; Nifedipine; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Sympathomimetics | 2005 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Cardiovascular Agents; Cohort Studies; Drug Utilization; Endothelium, Vascular; Follow-Up Studies; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Models, Biological; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Precursors; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Stroke; Thrombosis; Treatment Outcome | 2007 |
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Cough; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Felodipine; Female; Headache; Humans; Hypertension; Incidence; Losartan; Male; Middle Aged; Respiratory Tract Infections | 1995 |
Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Atenolol; Chi-Square Distribution; Child; Child, Preschool; Echocardiography; Female; Humans; Infant; Logistic Models; Losartan; Male; Marfan Syndrome; Reproducibility of Results | 2013 |
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Enalapril; Humans; Hypertension; Lisinopril; Losartan; Randomized Controlled Trials as Topic | 2014 |
133 trial(s) available for atenolol and losartan
| Article | Year |
|---|---|
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Prospective Studies; Pulse; Tetrazoles; Time Factors | 1995 |
Efficacy and safety of losartan.
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enalapril; Felodipine; Humans; Hypertension; Imidazoles; Losartan; Placebos; Tetrazoles | 1995 |
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Asthenia; Atenolol; Biphenyl Compounds; Cough; Dizziness; Double-Blind Method; Fatigue; Felodipine; Female; Headache; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Placebos; Respiratory Tract Infections; Safety; Tetrazoles | 1995 |
Losartan potassium as initial therapy in patients with severe hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Renin-Angiotensin System; Tetrazoles; Treatment Outcome | 1995 |
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Losartan; Male; Middle Aged; Research Design; Tetrazoles; Treatment Outcome | 1997 |
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Body Mass Index; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Sex Factors | 1998 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; Buttocks; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Vascular Resistance; Vasodilation | 2000 |
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Diuretics; Double-Blind Method; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Single-Blind Method; Sleep Apnea, Obstructive; Sodium Chloride Symporter Inhibitors | 2000 |
The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Systole; Treatment Outcome | 2000 |
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies | 2000 |
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis | 2000 |
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Diastole; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Heart Atria; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Multivariate Analysis; Remission Induction; Treatment Outcome; Ventricular Function, Left | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Losartan; Male; Middle Aged; Regression Analysis | 2002 |
Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Humans; Hypertension; Losartan; Middle Aged | 2002 |
Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Treatment Outcome; Tunica Intima; Tunica Media | 2002 |
Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Neurotransmitter Agents; Safety | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Middle Aged; Prospective Studies; Risk Assessment | 2002 |
Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Clinical Protocols; Diabetes Complications; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Morbidity; Risk | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Stroke; Systole; Treatment Outcome | 2002 |
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Ultrasonography; Ventricular Function, Left | 2002 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors | 2003 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Risk Factors | 2003 |
[Reduction of cardiovascular events with lorsartan? The LIFE Study].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cerebral Infarction; Double-Blind Method; Humans; Hypertension; Losartan; Middle Aged; Myocardial Infarction; Receptor, Angiotensin, Type 1; Survival Rate; Treatment Outcome | 2003 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Remission Induction; Single-Blind Method | 2003 |
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Losartan; Male; Middle Aged; Regression Analysis; Risk Factors | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Diabetes Complications; Double-Blind Method; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Racial Groups; Remission Induction; Risk Factors; Sex Factors; Treatment Outcome | 2003 |
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged | 2003 |
Influence of losartan and atenolol on memory function in very elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cognition; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Memory; Psychological Tests | 2003 |
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; Endpoint Determination; Female; Follow-Up Studies; Hemoglobins; Humans; Hypertension, Renal; Losartan; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Treatment Outcome; Uric Acid | 2004 |
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Asian People; Atenolol; Black People; Blood Pressure; Drug Therapy, Combination; Europe; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Treatment Outcome; United States; White People | 2004 |
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; European Union; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Stroke | 2004 |
[Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. Results of LIFE study].
Topics: Anti-Arrhythmia Agents; Atenolol; Humans; Hypertrophy, Left Ventricular; Losartan; Remission Induction | 2003 |
[Treatment of hypertension in patients with left ventricular hypertrophy].
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged | 2004 |
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Remission Induction; Sex Factors; Time Factors; Ultrasonography | 2004 |
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Time Factors | 2004 |
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Catecholamines; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Time Factors | 2004 |
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Remission Induction; Time Factors; Ultrasonography | 2004 |
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Treatment Outcome | 2004 |
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Stroke; Ultrasonography | 2004 |
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; Collagen; Double-Blind Method; Female; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardium; Peptide Fragments; Treatment Outcome; Ultrasonography | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Risk Factors; Stroke | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Organ Size; Prospective Studies; Treatment Outcome; Ultrasonography | 2004 |
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy).
Topics: Aged; Aged, 80 and over; Aortic Valve; Atenolol; Female; Heart Valve Diseases; Humans; Losartan; Male; Middle Aged; Sclerosis | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Morbidity; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ultrasonography; Ventricular Remodeling | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Comorbidity; Diabetes Complications; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Severity of Illness Index; Stroke; Treatment Outcome | 2005 |
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Severity of Illness Index | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Risk Factors; Survival Analysis | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Atrial Fibrillation; Cause of Death; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Risk Factors; Secondary Prevention; Stroke; Survival Rate | 2005 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Myocardial Infarction; Regression Analysis; Smoking; Stroke | 2004 |
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Forearm; Humans; Hypertension; Insulin; Insulin Resistance; Losartan; Middle Aged; Peripheral Vascular Diseases; Vascular Resistance | 2005 |
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epidemiologic; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Multicenter Studies as Topic; Stroke; Systole; Treatment Outcome | 2005 |
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
Topics: Aged; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments | 2005 |
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Obesity; Proportional Hazards Models; Risk Assessment; Somatotypes | 2005 |
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
Topics: Aged; Atenolol; Blood Pressure; Carotid Arteries; Female; Humans; Hypertension; Losartan; Male; Time; Treatment Outcome; Tunica Intima; Ultrasonography | 2005 |
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atenolol; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Treatment Outcome | 2005 |
Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electrocardiography; Follow-Up Studies; Heart Rate; Humans; Hypertension; Losartan; Middle Aged; Prospective Studies; Treatment Outcome | 2005 |
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Predictive Value of Tests; Prognosis; Risk Factors; Sclerosis; Survival Analysis; Treatment Outcome | 2005 |
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Losartan; Male; Middle Aged; Risk Factors; Treatment Outcome | 2005 |
Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Baroreflex; Blood Pressure; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Losartan; Male; Middle Aged; Time Factors; Treatment Outcome | 2006 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Predictive Value of Tests; Risk; Treatment Outcome | 2006 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenolol; Carotid Artery Diseases; Disease Progression; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Stroke; Time Factors | 2006 |
Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Hemodynamics; Humans; Hypertension; Losartan | 2005 |
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis; Treatment Outcome | 2006 |
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors; Treatment Outcome | 2006 |
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Creatinine; Endpoint Determination; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; ROC Curve; Scandinavian and Nordic Countries | 2006 |
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Risk | 2006 |
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Echocardiography, Doppler, Color; Electrocardiography; Exercise; Female; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Oxygen Consumption; Physical Endurance | 2006 |
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Biomarkers; Blood Pressure; Female; Fibrosis; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Procollagen | 2006 |
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Predictive Value of Tests; Risk Assessment; Stroke | 2007 |
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Diastole; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Pulse; Systole; Treatment Outcome | 2007 |
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Dinoprost; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypertension; Insulin Resistance; Losartan; Male; Middle Aged; Oxidative Stress; Regional Blood Flow; Research Design; Treatment Outcome; Vasodilation | 2007 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged | 2007 |
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analysis; Endpoint Determination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Life Expectancy; Losartan; Male; Middle Aged; Netherlands; Risk; Stroke | 2007 |
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemoglobins; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Stroke | 2007 |
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardiography; Female; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged | 2007 |
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; Blood Pressure; Cytokines; Diastole; Female; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Systole; Ultrasonography | 2007 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Complications; Epidemiologic Methods; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Motor Activity; Myocardial Infarction; Treatment Outcome | 2007 |
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Atenolol; Humans; Losartan; Marfan Syndrome; Outcome Assessment, Health Care; Research Design | 2007 |
Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Time Factors | 2007 |
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Losartan; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Regression Analysis; Risk Factors; Severity of Illness Index | 2008 |
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography, Doppler; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Linear Models; Losartan; Male; Middle Aged; Prevalence; Sex Characteristics; Sex Distribution; Systole | 2008 |
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Risk Reduction Behavior; Sex Distribution; Stroke | 2008 |
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis | 2008 |
Efficacy of exercise, losartan, enalapril, atenolol and rilmenidine in subjects with blood pressure hyperreactivity at treadmill stress test and left ventricular hypertrophy.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Enalapril; Exercise Test; Exercise Therapy; Female; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Oxazoles; Renin-Angiotensin System; Rilmenidine; Sympathetic Nervous System | 2009 |
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Hemoglobins; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis | 2009 |
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diastole; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Medical History Taking; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Stress, Mechanical; Systole | 2009 |
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Risk Factors; Stroke Volume; Ventricular Function, Left | 2009 |
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardiography; Epidemiologic Methods; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged | 2009 |
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Kaplan-Meier Estimate; Losartan; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2008 |
Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Double-Blind Method; Female; Fibrinolysis; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Renin-Angiotensin System; Thrombophilia; Tissue Plasminogen Activator; von Willebrand Factor | 2010 |
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study.
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography; Female; Heart Failure; Humans; Incidence; Likelihood Functions; Losartan; Male; Middle Aged; Placebos | 2009 |
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged | 2009 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors; Uric Acid | 2010 |
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Losartan; Male; Middle Aged; Treatment Outcome | 2010 |
How to avoid discontinuation of antihypertensive treatment: The experience in São Paulo, Brazil.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Clinical Protocols; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Medication Adherence; Middle Aged; Telephone | 2010 |
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prospective Studies; Risk Assessment | 2011 |
[Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
Topics: Adolescent; Adult; Antihypertensive Agents; Aorta; Aortic Diseases; Atenolol; Child; Child, Preschool; Double-Blind Method; Electrocardiography; Female; Humans; Losartan; Magnetic Resonance Imaging; Male; Marfan Syndrome; Middle Aged; Young Adult | 2011 |
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Leukocytes; Losartan; Male; Middle Aged; Risk Factors; Telomere; Treatment Outcome | 2011 |
In-treatment stroke volume predicts cardiovascular risk in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Losartan; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Regression Analysis; Risk Factors; Stroke; Stroke Volume; Ventricular Function, Left | 2011 |
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Topics: Aged; Alcohol Drinking; Analysis of Variance; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Factors; Smoking | 2012 |
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Hypokalemia; Losartan; Male; Prospective Studies; Ultrasonography | 2012 |
Impact of lower achieved blood pressure on outcomes in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cause of Death; Comorbidity; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Risk Factors; Treatment Outcome; United States | 2012 |
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Losartan; Male; Middle Aged; Risk Factors | 2012 |
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged | 2012 |
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Regression Analysis; Treatment Outcome | 2012 |
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Comorbidity; Double-Blind Method; Echocardiography; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Regression Analysis; Risk Factors | 2012 |
Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Atenolol; Child; Dilatation, Pathologic; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Losartan; Male; Marfan Syndrome; Pilot Projects; Propranolol; Treatment Outcome; Young Adult | 2013 |
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Risk Factors | 2013 |
Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm, Thoracic; Atenolol; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Losartan; Male; Marfan Syndrome; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Systole | 2014 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; Death; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Organ Size; Proportional Hazards Models; Stroke | 2014 |
A multicentric double blind randomised controlled trial of atenolol versus losartan as first line drug for mild to moderate essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; White Coat Hypertension | 2013 |
Atenolol versus losartan in children and young adults with Marfan's syndrome.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Aortic Valve Insufficiency; Atenolol; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Infant; Linear Models; Losartan; Male; Marfan Syndrome; Treatment Outcome; Young Adult | 2014 |
A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Atenolol; Double-Blind Method; Echocardiography; Endothelium, Vascular; Female; Humans; Loeys-Dietz Syndrome; Losartan; Male; Marfan Syndrome; Pilot Projects; Pulse Wave Analysis; Treatment Outcome | 2015 |
Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; Atenolol; Boston; Double-Blind Method; Echocardiography, Doppler, Pulsed; Female; Humans; Losartan; Male; Manometry; Marfan Syndrome; Middle Aged; Pulse Wave Analysis; Time Factors; Treatment Outcome; Vascular Stiffness; Ventricular Function, Left | 2015 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Digoxin; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Lipoproteins, HDL; Losartan; Male; Middle Aged; Risk | 2015 |
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Regression Analysis; Risk Factors; Systole; Treatment Outcome | 2015 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Creatinine; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Ultrasonography | 2015 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Female; Heart Rate; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Oxygen; Prevalence; Stroke; Treatment Outcome | 2015 |
Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Child; Child, Preschool; Double-Blind Method; Humans; Losartan; Magnetic Resonance Angiography; Magnetic Resonance Imaging, Cine; Marfan Syndrome; Middle Aged; Treatment Outcome; Young Adult | 2016 |
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Proportional Hazards Models; Sex Factors; Stroke; Stroke Volume; Vascular Stiffness | 2017 |
Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Risk Factors; Survival Rate; Treatment Outcome; United States | 2017 |
The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mortality; Patient Care Planning; Proportional Hazards Models; Systole; Treatment Outcome; United States | 2018 |
Impact of achieved systolic blood pressure on renal function in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Glomerular Filtration Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Function Tests; Losartan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors | 2016 |
Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.
Topics: Adolescent; Aorta; Aortic Diseases; Atenolol; Cardiac Imaging Techniques; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Linear Models; Losartan; Marfan Syndrome; Prognosis; Proportional Hazards Models; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome; Vascular Stiffness | 2018 |
Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Aortic Dissection; Atenolol; Dilatation, Pathologic; Disease Progression; Female; Follow-Up Studies; Humans; Losartan; Magnetic Resonance Imaging, Cine; Male; Marfan Syndrome; Young Adult | 2018 |
Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome.
Topics: Adolescent; Adult; Antihypertensive Agents; Atenolol; Child; Child, Preschool; Female; Health Status Indicators; Humans; Losartan; Male; Marfan Syndrome; Patient Reported Outcome Measures; Quality of Life; Severity of Illness Index; Young Adult | 2019 |
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Atenolol; Child; Child, Preschool; Cytochrome P-450 CYP2C9; DNA; Female; Follow-Up Studies; Gene Expression Regulation; Genotype; Humans; Infant; Losartan; Male; Marfan Syndrome; Receptors, Adrenergic, beta-1; Retrospective Studies; Young Adult | 2020 |
Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Child; Female; Humans; Losartan; Male; Marfan Syndrome; Prescriptions; Young Adult | 2023 |
The EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases (TREAT-SVDs) trial: Study protocol for a randomised crossover trial.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cross-Over Studies; Humans; Losartan; Prospective Studies; Randomized Controlled Trials as Topic | 2023 |
133 other study(ies) available for atenolol and losartan
| Article | Year |
|---|---|
Interaction of digoxin with antihypertensive drugs via MDR1.
Topics: Animals; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Digoxin; Drug Interactions; Humans; Time Factors | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Beta adrenoceptor blockade in rabbit inhibits the renin-releasing effect of AT1 receptor antagonist losartan.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Biphenyl Compounds; Blood Pressure; Heart Rate; Imidazoles; Indomethacin; Losartan; Male; Rabbits; Renin; Tetrazoles | 1993 |
Angiotensin II is the mediator of the increase in hepatic angiotensinogen synthesis after bilateral nephrectomy.
Topics: Adrenalectomy; Angiotensin II; Angiotensinogen; Animals; Atenolol; Biphenyl Compounds; Imidazoles; Kidney; Liver; Losartan; Male; Nephrectomy; Osmolar Concentration; Postoperative Period; Rats; Rats, Wistar; Renin; Tetrazoles; Time Factors | 1993 |
Renin release induced by losartan (DuP 753), an angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Atenolol; Biphenyl Compounds; Dose-Response Relationship, Drug; Feedback; Imidazoles; Indomethacin; Injections, Intravenous; Losartan; Male; Meclofenamic Acid; Propranolol; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Receptors, Angiotensin; Renin; Sympathetic Nervous System; Tetrazoles | 1993 |
Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cells, Cultured; Endothelium, Vascular; Female; Gene Expression Regulation; Humans; Hypertension; Intercellular Adhesion Molecule-1; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Umbilical Veins | 1999 |
Antihypertensive monotherapy and cardiovascular responses to an acoustic startle stimulus.
Topics: Acoustic Stimulation; Adrenergic alpha-Agonists; Analysis of Variance; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Losartan; Male; Middle Aged; Prazosin; Reflex, Startle; Stroke Volume; Vascular Resistance | 2001 |
[When hypertension damages microcirculation. A-II-antagonist corrects damage, beta blocker does not].
Topics: Atenolol; Clinical Trials as Topic; Follow-Up Studies; Humans; Hypertension; Losartan; Microcirculation; Vascular Resistance | 2001 |
[A possible adverse effect from the association of losartan-mefenamic acid in hemodialysis].
Topics: Adult; Antihypertensive Agents; Atenolol; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Furosemide; Glomerulonephritis, IGA; Humans; Hypertension; Losartan; Mefenamic Acid; Renal Dialysis | 2001 |
Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Captopril; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypertension; Imidazoles; Losartan; Multicenter Studies as Topic; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2001 |
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Blood Pressure; Creatinine; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Pulse; Randomized Controlled Trials as Topic | 2002 |
[Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Prognosis; Randomized Controlled Trials as Topic; Stroke; Survival Rate | 2002 |
ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
[Marketing of researchers--lack of judgment or a new trend?].
Topics: Advertising; Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Ethics, Medical; Evidence-Based Medicine; Humans; Losartan; Marketing of Health Services; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Research Personnel; Sweden | 2002 |
[Marketing of the LIFE trial anticipates evaluation of the drug].
Topics: Advertising; Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Ethics, Medical; Humans; Losartan; Marketing of Health Services; Randomized Controlled Trials as Topic; Sweden | 2002 |
[LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Risk Factors | 2002 |
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Endpoint Determination; Female; Humans; Hypertension; Losartan; Male; Myocardial Infarction; Stroke; Treatment Outcome | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Losartan | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Heart Rate; Humans; Losartan; Risk Factors | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Losartan; Reproducibility of Results | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Humans; Losartan; Natriuretic Peptide, Brain | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Endpoint Determination; Humans; Losartan; Stroke; Treatment Outcome | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diuretics; Humans; Hypertension; Losartan; Research Design | 2002 |
[Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Survival Rate | 2002 |
No morbidity-mortality. Commentary.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabetes Complications; Diabetes Mellitus; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Morbidity; Patient Selection | 2002 |
[Preventing stroke. Which antihypertensive drugs can do it better?].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2002 |
[Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Research Design | 2002 |
Was the LIFE trial independent?
Topics: Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Research Support as Topic; Survival Rate; Sweden; Treatment Outcome | 2002 |
Was the LIFE trial independent?
Topics: Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Research Support as Topic; Survival Rate; Sweden; Treatment Outcome | 2002 |
[Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Receptor, Angiotensin, Type 1; Survival Rate; Systole; Treatment Outcome | 2002 |
[German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1 | 2002 |
[What are the consequences of the LIFE Study for general practice].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1 | 2002 |
Differential effects of antihypertensive drug therapy on arterial compliance.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Enalapril; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Treatment Outcome; Vascular Resistance | 2002 |
New strategies for prevention of ischemic stroke: the LIFE study.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome | 2003 |
[Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cause of Death; Coronary Disease; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Randomized Controlled Trials as Topic | 2002 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Carbazoles; Carvedilol; Drug Approval; Humans; Hypertension; Losartan; Middle Aged; Myocardial Infarction; Propanolamines; Racial Groups; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk; Stroke; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Treatment Outcome | 2003 |
More on the LIFE study.
Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Drug Industry; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Survival Rate; Sweden | 2003 |
More on the LIFE study.
Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Data Collection; Drug Industry; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Sweden | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Losartan; Stroke | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Losartan; Stroke | 2003 |
[Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Time Factors | 2003 |
[Losartan in isolated systolic hypertension--convincing results of a LIFE sub-group study].
Topics: Aged; Antihypertensive Agents; Atenolol; Cause of Death; Double-Blind Method; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate | 2003 |
The LIFE study: the straw that should break the camel's back.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke | 2003 |
[Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Cause of Death; Clinical Trials as Topic; Humans; Hypertension; Losartan; Receptor, Angiotensin, Type 1; Treatment Outcome | 2003 |
Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged | 2003 |
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Female; Humans; Hypertension; Losartan; Male | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Double-Blind Method; Electrocardiography; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Time Factors | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
Losartan and atenolol on hypertension induced by adenosine receptor blockade.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 2 Receptor Blockers; Animals; Atenolol; Cell Division; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Hypertension; Infusion Pumps, Implantable; Infusions, Parenteral; Losartan; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Myocardium; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Receptors, Adrenergic, beta-1; Receptors, Purinergic P1; Renin; Tail; Xanthines | 2003 |
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Losartan; Ramipril; Stroke | 2003 |
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Basement Membrane; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Hypertrophy; Kidney Failure, Chronic; Kidney Glomerulus; Losartan; Male; Microscopy, Electron; Nephrectomy; Proteinuria; Rats; Rats, Wistar; Systole; Time Factors | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Fibrinolytic Agents; Humans; Hypertension; Losartan; Treatment Outcome | 2003 |
The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives.
Topics: Adenine; Adult; Aged; Alleles; Antihypertensive Agents; Atenolol; Collagen Type I; Cytosine; Elasticity; Female; Gene Frequency; Genotype; Heart; Humans; Hypertension; Losartan; Male; Middle Aged; Polymorphism, Genetic; Receptor, Angiotensin, Type 1 | 2003 |
Proportion of treatment effect (PTE) explained by a surrogate marker.
Topics: Antihypertensive Agents; Atenolol; Biomarkers; Confidence Intervals; Data Interpretation, Statistical; Humans; Hypertension; Losartan; Models, Statistical; Monte Carlo Method; Treatment Outcome; Uric Acid | 2003 |
[To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Humans; Hypertension; Losartan; Middle Aged; Patient Compliance; Risk Factors; Stroke | 2003 |
Effects of losartan in hypertension without vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Losartan | 2004 |
The LIFE Trial in 2004.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Losartan | 2004 |
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Survival Analysis | 2004 |
Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure.
Topics: Animals; Atenolol; Disease Models, Animal; Kidney; Kidney Cortex; Kidney Failure, Chronic; Losartan; Nephrectomy; Oxidative Stress; Rats | 2004 |
[When compliance doesn't work out. Calculate the risk of stroke for hypertensive patients!].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Causality; Clinical Trials as Topic; Humans; Hypertension; Losartan; Patient Education as Topic; Risk; Stroke; Treatment Refusal | 2004 |
[Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
Topics: Alzheimer Disease; Antihypertensive Agents; Atenolol; Cerebral Infarction; Clinical Trials as Topic; Humans; Hypertension; Losartan; Treatment Outcome | 2004 |
[Optimizing antihypertensive therapy. In 5 years 35,000 strokes are preventable].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cerebral Infarction; Clinical Trials as Topic; Cross-Sectional Studies; Europe; Humans; Hypertrophy, Left Ventricular; Losartan; Middle Aged | 2004 |
[A problem that should be recognized. Greater risk of diabetes with antihypertensive drugs?].
Topics: Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucose Tolerance Test; Humans; Losartan; Randomized Controlled Trials as Topic; Risk Factors | 2004 |
Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective.
Topics: Aged; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Humans; Hypertension; Life Expectancy; Losartan; Male; Pharmacoepidemiology; Retrospective Studies; Switzerland | 2004 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Cause of Death; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Survival Rate | 2005 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke | 2005 |
Keeping tabs on your heart while treating BP.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan | 2005 |
Letter regarding article by Devereux et al, "regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial".
Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Ventricular Function, Left | 2005 |
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; National Health Programs; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Sweden; Treatment Outcome | 2005 |
Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atenolol; Blood Pressure; Cardiomegaly; Doxazosin; Drug Therapy, Combination; Echocardiography; Heart Rate; Hypertension; Losartan; Male; Natriuretic Peptide, Brain; Rats; Rats, Inbred SHR; RNA, Messenger | 2005 |
Pulse pressure and antihypertensive agents.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Humans; Hypertension; Losartan; Stroke | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; Atenolol; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk; Stroke | 2005 |
Enlarged hearts, larger threats. But reducing heart-muscle mass can blunt cardiac dangers.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertrophy, Left Ventricular; Losartan | 2005 |
Black pearl in the LIFE study: angiotensin-II receptor blockade on atrial fibrillation for future personalized medicine.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Black or African American; Humans; Losartan; Recurrence; White People | 2005 |
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Creatinine; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2006 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies; Cost-Benefit Analysis; Critical Care; Female; Health Care Costs; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Models, Economic; Myocardial Infarction; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke; Stroke Rehabilitation | 2006 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Diseases; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Metabolic Syndrome; Primary Prevention; Prognosis; Risk Assessment; Risk Factors; Time Factors | 2006 |
[Plus point -- risk reduction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Losartan; Placebos; Risk; Risk Factors; Stroke; Time Factors | 2006 |
[Kidney protection leads to heart protection, too].
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Kidney Diseases; Losartan; Risk Factors; Time Factors | 2006 |
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Autonomic Nervous System; Blood Pressure; Cardiovascular System; Heart Rate; Hydrochlorothiazide; Hypertension; Losartan; Male; Ramipril; Rats; Rats, Wistar; Sympathetic Nervous System | 2006 |
[Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Decision Trees; Health Care Costs; Humans; Hypertension; Losartan; Models, Economic; Quality-Adjusted Life Years | 2006 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Losartan; Manometry; Perindopril; Ultrasonography, Doppler | 2007 |
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Comorbidity; Diabetes Mellitus; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2007 |
Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1 | 2007 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Diabetes Complications; Drug Therapy, Combination; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk Factors; Stroke | 2008 |
Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Capillaries; Disease Models, Animal; Enalapril; Heart Ventricles; Hypertension; Losartan; Male; Microcirculation; Microscopy, Video; Muscle, Skeletal; Nifedipine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Skin | 2008 |
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Brachial Artery; Cardiac Volume; Cross-Sectional Studies; Echocardiography; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Pulse; Ventricular Function | 2008 |
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ultrasonography | 2008 |
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug Therapy, Combination; France; Humans; Hydrochlorothiazide; Hypertension; Indapamide; Losartan; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Captopril; Hydrochlorothiazide; Losartan; Mice; Nifedipine; RNA, Messenger; Telmisartan | 2009 |
Slower heart rates for healthy hearts: time to redefine tachycardia?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Electrocardiography; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Reference Values; Risk Assessment; Risk Factors; Tachycardia; Time Factors; Treatment Outcome | 2008 |
Effects of anti-hypertensive drugs on esophageal body contraction.
Topics: Adult; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Esophagus; Gastrointestinal Motility; Humans; Losartan; Male; Muscle, Smooth; Nifedipine; Peristalsis; Sympatholytics | 2010 |
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic | 2010 |
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
Topics: Aged; Albuminuria; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol, HDL; Electrocardiography; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Regression Analysis; Risk | 2010 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Electrocardiography; Female; Heart Atria; Heart Rate; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk | 2010 |
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Smoking; Stroke; Treatment Outcome | 2011 |
Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data.
Topics: Antihypertensive Agents; Atenolol; Captopril; Cardiovascular Diseases; Cost of Illness; Developing Countries; Health Services Accessibility; Humans; Hydrochlorothiazide; Losartan; Nifedipine; World Health Organization | 2010 |
Is hydrochlorothiazide more effective on LVH in nonresponders to losartan than in those to atenolol?
Topics: Antihypertensive Agents; Atenolol; Electrocardiography; Humans; Hydrochlorothiazide; Hypertrophy, Left Ventricular; Losartan; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Atenolol; Hypertension; Losartan; Male; Malondialdehyde; Nitric Oxide Synthase Type III; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Artery; Renin-Angiotensin System; Sodium Chloride, Dietary; Superoxides | 2010 |
Simultaneous spectrophotometric estimation of Hydrochlorothiazide, Atenolol and Losartan potassium in tablet dosage form.
Topics: Antihypertensive Agents; Atenolol; Calibration; Hydrochlorothiazide; Losartan; Spectrophotometry, Ultraviolet; Tablets | 2009 |
Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension.
Topics: Adult; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Atenolol; Captopril; Case-Control Studies; Female; Humans; Hydrochlorothiazide; Hypertension; In Vitro Techniques; Inflammation Mediators; Interleukin-1beta; Lipopolysaccharides; Losartan; Male; Middle Aged; Neutrophils | 2011 |
Effects of antihypertensive drugs on specific harmonic indices of the pulse waveform in normotensive Wistar Kyoto rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Losartan; Male; Models, Animal; Models, Cardiovascular; Pulsatile Flow; Rats; Rats, Inbred WKY | 2012 |
An economic evaluation of antihypertensive therapies based on clinical trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Costs; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic | 2012 |
Blockade of renin-angiotensin system prevents micturition dysfunction in renovascular hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Captopril; Cyclic AMP; Electric Stimulation; Female; Hypertension, Renovascular; Losartan; Male; Muscle Relaxation; Rats; Renin-Angiotensin System; Urethra; Urinary Bladder; Urination | 2014 |
Of Marfan's syndrome, mice, and medications.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome | 2014 |
Atenolol versus Losartan in Marfan's Syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome | 2015 |
Atenolol versus Losartan in Marfan's Syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome | 2015 |
Atenolol versus Losartan in Marfan's Syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome | 2015 |
Atenolol versus Losartan in Marfan's Syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome | 2015 |
[Drugs news].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Anti-Obesity Agents; Anticonvulsants; Aorta; Aortic Aneurysm; Atenolol; Cleft Palate; Female; Fructose; Hemangioma; Humans; Losartan; Male; Marfan Syndrome; Pregnancy; Prenatal Exposure Delayed Effects; Skin Neoplasms | 2015 |
Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; Atenolol; Female; Humans; Losartan; Male; Marfan Syndrome; Vascular Stiffness | 2016 |
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Atrial Function, Left; Electrocardiography; Female; Follow-Up Studies; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Losartan; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Random Allocation; Risk Factors; Stroke | 2016 |
Thermodynamic compatibility between cyclodextrin supramolecular complexes and surfactant.
Topics: Antihypertensive Agents; Atenolol; beta-Cyclodextrins; Losartan; Magnetic Resonance Spectroscopy; Sodium Dodecyl Sulfate; Spectroscopy, Fourier Transform Infrared; Surface-Active Agents; Thermodynamics | 2018 |
Cytotoxic and genotoxic effects of antihypertensives distributed in Brazil by social programs: Are they safe?
Topics: Antihypertensive Agents; Atenolol; Brazil; Captopril; Cell Survival; Cells, Cultured; DNA Damage; Dose-Response Relationship, Drug; Enalapril; Government Programs; Humans; Hydrochlorothiazide; Hypertension; Losartan; Lymphocytes; Macrophages; Male; Mutagenicity Tests; Program Evaluation; Propranolol | 2018 |
Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Arrhythmias, Cardiac; Atenolol; Child; Child, Preschool; Echocardiography; Electrocardiography, Ambulatory; Female; Humans; Infant; Losartan; Male; Marfan Syndrome; Retrospective Studies | 2018 |
Losartan for the Treatment of Marfan Syndrome: Hope Fades.
Topics: Angiotensin II Type 1 Receptor Blockers; Atenolol; Dilatation; Humans; Losartan; Marfan Syndrome | 2018 |
Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience.
Topics: Adolescent; Anti-Arrhythmia Agents; Atenolol; Black or African American; Child; Child, Preschool; Clinical Protocols; Female; Humans; Infant; Losartan; Male; Marfan Syndrome; Medication Adherence; Patient Compliance; Patient Selection; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Young Adult | 2020 |
Effect of Losartan or Atenolol on Children and Young Adults With Bicuspid Aortic Valve and Dilated Aorta.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atenolol; Bicuspid Aortic Valve Disease; Child; Child, Preschool; Dilatation, Pathologic; Female; Humans; Infant; Infant, Newborn; Losartan; Male; Pilot Projects; Retrospective Studies; Young Adult | 2021 |
Racial and ethnic differences in response to treatment for Marfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Aorta; Atenolol; Child; Humans; Losartan; Marfan Syndrome; Young Adult | 2021 |
Comparative Effect of Losartan and Atenolol on Heart Rate Variability in Untreated Essential Hypertensive Patients by Power Spectral Analysis.
Topics: Adult; Atenolol; Bangladesh; Heart Rate; Humans; Longitudinal Studies; Losartan; Male; Middle Aged | 2022 |
First report on the occurrence of pharmaceuticals and cocaine in the coastal waters of Santa Catarina, Brazil, and its related ecological risk assessment.
Topics: Acetaminophen; Atenolol; Brazil; Caffeine; Carbamazepine; Chromatography, Liquid; Cocaine; Cosmetics; Diclofenac; Ecosystem; Environmental Monitoring; Humans; Losartan; Orphenadrine; Pharmaceutical Preparations; Risk Assessment; Sewage; Solid Waste; Tandem Mass Spectrometry; Water; Water Pollutants, Chemical | 2022 |
Occurrence, ecological risk assessment and prioritization of pharmaceuticals and abuse drugs in estuarine waters along the São Paulo coast, Brazil.
Topics: Acetaminophen; Atenolol; Brazil; Caffeine; Carbamazepine; Chromatography, Liquid; Cocaine; Diclofenac; Ecosystem; Environmental Monitoring; Furosemide; Illicit Drugs; Losartan; Orphenadrine; Pharmaceutical Preparations; Risk Assessment; Rivers; Tandem Mass Spectrometry; Water Pollutants, Chemical | 2022 |